CRISPR Therapeutics AG (1CG.SG)
| Previous Close | 40.80 |
| Open | 38.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 37.80 - 38.40 |
| 52 Week Range | 37.80 - 40.80 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
CRISPR Therapeutics' (NASDAQ:CRSP) investors will be pleased with their favorable 63% return over the last five years
It might be of some concern to shareholders to see the CRISPR Therapeutics AG ( NASDAQ:CRSP ) share price down 17% in...
- Yahoo Finance Video
Sickle cell gene editing faces market hurdles: Analyst
The FDA approved a gene editing treatment for sickle cell disease to alleviate severe, recurrent pain crises. Casgevy, developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), is a one-time treatment that harnesses gene editing advancements. However, the therapy faces accessibility hurdles, according to Wedbush Managing Director David Nierengarten. Despite providing a lifelong cure, he believes the complex procedure and recovery alongside the expensive price tag will be challenging to market to patients. Nierengarten believes uptake will be limited to most acute cases given process difficulties. The length of time for treatment preparation, hospitalization, and healing poses barriers. Low enrollment in clinical trials is "not surprising" per Nierengarten, as "the real barrier here is the procedure itself." Accessing facilities able to perform the bone marrow transplant involved also raises logistics issues. He notes trial sites were in areas with small sickle cell populations. "The time it takes to do it and the difficulties involved with it" are key obstacles, Nierengarten told Yahoo Finance. Though transformative for patients, real-world availability of the therapy faces multiple constraints. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
- Yahoo Finance Video
FDA approves gene-editing therapy for sickle cell disease
The FDA approved gene-editing therapy Casgevy to treat sickle cell disease. Developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), the one-time treatment harnesses gene editing advancements. Vertex CEO Dr. Reshma Kewalramani says the approach involves extracting a patient's stem cells, correcting the defect in those cells using CRISPR gene editing tools, then re-infusing the edited cells into the patient - relieving painful symptoms. Patients who undergo this $2.2 million procedure may eliminate painful sickle cell crises called VOC's. Kewalramani contrasts the cost against the $4-6 million lifetime price tag for conventional sickle cell management. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
